Clinical ResultsAll 3 patients achieved primary efficacy renal response (PERR), indicating a positive outcome for the treatment.
Efficacy And SafetyFT819 has demonstrated a clean safety profile thus far, aside from a single case of grade 2 CRS in a patient.
Regulatory ProgressFate plans to meet with the FDA to discuss potential pivotal study design in SLE/LN, aiming to remove the current hospitalization requirement post-treatment.